2. SURVEILLANCE OF TUBERCULOSIS IN EUROPE: Report on tuberculosis cases notified in 2006”.

Bibliografia

1. Global tuberculosis control: surveillance, planning, financing: WHO report 2008.

Ed. WHO Library Cataloguing-in-Publication Data.

2. SURVEILLANCE OF TUBERCULOSIS IN EUROPE: Report on tuberculosis cases notified in 2006”.

3. Epidemiologia della tubercolosi in Italia (anni 1995-2005)”. Fonte: Ministero della Salute - DG della Prevenzione Sanitaria – Ufficio V – Malattie Infettive e Profilassi Internazionale.

4. Keers RY. Pulmonary tuberculosis: a journey down the centuries. In “A Clinician’s Guide to Tuberculosis”. Iseman.MD. Ed Lippincott, Williams & Wilkins, 2000.

5. Shinnik TM, Good RC. Mycobacterial taxonomy. Eur J Clin Microbiol Infect Dis”

1994; 13: 884-901.

6. Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person- to-person transmission in UK. Evans JT, Smith EG, Banerjee A, et al. The Lancet 2007; 369: 1270-1276.

7. McNeil MR, Brennan PJ. Structure, function, and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug

resistance: some thoughts and possibilities arising from recent structural information. Res Microbiol 1991; 142: 451-463.

8. Chan J, Fan X, Hunter SW, Brennan PJ, Bloom BR. Lipo-arabinomannan: a possible

virulence factor involved in persistence of Mycobacterium tuberculosis within

macrophages. Infect Immun 1991; 59: 1755-1761.

9. Barnes P, Fong S, Brennan P, Twomey P, et al.. Local production of tumor necrosis factor and IFN-γ in tuberculous pleurits. J Immunol 1990; 145: 149-154.

10. Bloch H. Studies on the virulence of tubercle bacilli: isolation and biological proprieties of a constituent of virulent organism. J Exp Med 1950; 91: 197-218.

11. Bloch H, Sorkin E, Erlenmeyer H. A toxic lipid component of the tubercle bacillus (“cord factor”), I: isolation from petroleum ether extracts of young bacterial cultures. Am Rev Tuberc 1955; 71: 361-370.

12. Noll H, Bloch H. A toxic lipid component of the tubercle bacillus (“cord factor”), II:

occurrence in chloroform extracts of young and older bacterial cultures. Am Rev Tuberc 1953; 67: 828-851.

13. Asselineau J, Bloch H, Lederer E. A toxic lipid component of the tubercle bacillus (“cord factor”), III: occurrence and distribution in various bacterial extracts. Am Rev Tuberc 1953; 67: 853-858.

14. Noll H, Bloch H, Asselineau J, Lederer E. The chemical structure of the cord factor of Mycobacterium tuberculosis. Biochem Biophys Acta 1956; 20: 299-317.

15. Riley RL, O’Grady F. Airborne infection: transmission and control. 1961 ed.

MacMillan New York.

16. Riley R, Wells W, Mills C, et al. Air Hygiene in tuberculosis: quantitative studies of infectivity and control in a pilot ward. Am Rev Tuberc 1957; 75: 420-430.

17. Duguid J. The numbers and sites of origin of the droplets expelled during respiratory

activities. Edinburgh Med J 1945; 52:385.

18. Duguid J. Expulsion of pathogenic organisms from the respiratory tract. Br Med J 1946; 1: 245.

19. Sultan L, Lyka W, Mills C, et al. Tuberculosis disseminators: a study of the

variability of aerial infectivity of tuberculous patient. Am Rev Respir Dis 1960;

82:358.

20. Loudon RG, Romans WE. Cough frequency and infectivity in patients with pulmonary tuberculosis Am Rev Respir Dis 1969; 99:109-111.

21. Weinberg K, Parkman R. Age, the thymus and T-lymphocytes. N Engl J Med 1995;

332:182-183.

22. Saltzman RL, Peterson PK. Immunodeficency of the elderly. Rev In Dis 1987;

9:1127-1139.

23. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.

24. Kim SJ, Hong YP, Lew WJ et al. Incidence of pulmonary tuberculosis among diabetics. Tuberc Lung Dis 1995; 76:529-533.

25. Ruiz P, Gomez F, Schreiber A. Impaired function of macrophage Fc-gamma receptors in end-stage renal disease. N Engl J Med 1990;322: 717-722.

26. Clarke JR, Robinson DS, Coker RJ et al. AIDS and the lung update 1995. Role of the human immunodeficiency virus within the lung. Thoracs 1995; 50: 567-576.

27. Schleuger NW, Huberman R, Wolinsky N et al. Tuberculosis infection and disease among person seeking social services in New York City. Int J Tuberc Lung Dis 1997; 1:31-37.

28. Valway SE, Greifinger RB, Papania M et al. Multidrug-resistant tuberculosis in the New York State prison system 1990-1991. J Infect Dis 1994; 170:151-156.

29. Dannenberg AM. Delayed-type hypersensitivity and cell-mediated immunity in the

pathogenesis of tuberculosis. Immunol Today 1991; 12:228-233.

30. Dannenberg AM Jr., Rook Gaw. Pathogenesis of pulmonary tuberculosis: an

interplay of tissue-damaging and macrophage-activating immune responses-dual mechanism that control bacillary multiplication. In : BR Bloom, ed.Tuberculosis : pathogenesis, protection, and control. Washington DC: ASM, 1994

31. Schorey JS, Carroll MC, Brown EJ. A macrophage invasion mechanism of pathogenic mycobacteria. Science 1997; 277: 1091-1093.

32. Stokes RW, Haidl ID, Jefferies WA, Speert DP. Mycobacteria-macrophage interactions: macrophage phenotype determines the non-opsonic binding of Mycobacterium tuberculosis to murine macrophages”. J Immunol 1993; 151:

7067-7076.

33. Barnes PF, Grisso CL, Abrams JC et al. γ/δ T-lymphocytes in human tuberculosis. J Infect Dis 1992;165: 506-512.

34. Munk ME, Gtrill AJ, Kaufmann SHE. Target lysis and IL-2 secretion by γ/δ T- lymphocytes after activaction with bacteria. J Immunol 1990; 145:2434-2439.

35. Ito M, Kojiro N, Ikeda T et al. Increased proportions of peripheral blood γ/δ T-cells in patients with pulmonary tuberculosi.Chest1992;102: 195-197.

36. Modificazione alla scheda di notifica di caso di tubercolosi e micobatteriosi non tubercolare allegata al decreto ministeriale 15 dicembre 1990. Ministero della Sanità. Decreto ministeriale 29 luglio 1998 (pubblicato in Gazzetta Ufficiale n.

200 del 28 agosto 1998).

37. Linee-guida per il controllo della malattia tubercolare”, su proposta del Ministro della Sanità, ai sensi dell’art. 115, comma 1, lettera b), del decreto legislativo 31 marzo 1998, n. 112.

38. Mandler F., Passerini Tosi C., Scarparo C., Tortolì E., Piersimoni C. e il Comitato

AMCLI per lo Studio dei Micobatteri (CoSMic). Proposta di linee-guida per la

diagnosi microbiologica della Tubercolosi. Microbiologia Medica 1999; 14 (4):

313-330.

39. Siddui SH, Hwangbo CC, Silcox V et al. Rapid radiometric methods to detect and differentiate Mycobacterium Tuberculosis-M.Bovis from other mycobacterial species. Am Rev Respir Dis 1984;130: 634-640.

40. Luquin M, Gamboa F, Barcelò MG et al. Comparison of a biphasic non-radiometric system with Lowenstein-Jensen and BACTEC-460 system for recover of

mycobacteria from clinical specimens. Tubercle Lung Dis 1996; 77: 449-453.

41. Scarparo C, Ricordi P, Ruggiero G, Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility Mycobacterium

tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 2004; 42 (3): 1109-14.

42. Giampaglia CM, Martins MC, Veira GB, et al. Multicentre evaluation of an automated BACTEC 960 system for susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2007; 11(9): 986-91.

43. Tortoli E, Benedetti M, Fontenelli A, Simonetti MT. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the

radiometric BACTEC 460 TB method and the agar plate method of proportion. J Clin Microbiol 2002; 40(2): 607-10.

44. Smith M.B., Bergman J.S., Onoroto M., Mathews G., Woods G.L. Evaluation of the

enhanced amplified Mycobacterium tuberculosis direct test for direct detection of

Mycobacterium tuberculosis complex in respiratory specimens. Archives of

Pathology and Laboratory Medicine 1999; 123: 1101-1103.

45. Piersimoni C., Zitti P., Cimarelli M.E., Nista D., De Sio G. Clinical utility of Gen- Probe amplified Mycobacterium tuberculosis direct test compared with smear and culture for the diagnosis of pulmonary tuberculosis. Clinical Microbiology and Infection 1998; 4 (8): 442-446.

46. Callegaro A. Tecniche di amplificazione genica. Quaderni di Microbiologia Clinica:

Micobatteriologia, Milano, Biomedia 1999; 75-86.

47. Isemann MD. Tuberculosis. in Cecil Textbook of Medicine 22

Edition. Ed.

Goldmann L, Ausiello. 2004. 341: 1894-1902.

48. Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis 1997; 24: 291- 302.

49. Arnow PN, Flaherty JP. Fever of unknown origin. Lancet 1997; 350: 575-5800.

50. West J, Dollery C. Distribution of blood flow and ventilation-perfusion ratios in the lung measured with radioactive CO2. J Appl Physiol 1960; 15: 405-410.

51. Meylan P, Richmann DD, Kornbluth RS. Reduced intracellular growth of

mycobacteria in human macrophages at physiologic oxygen pressure. Am Rev Respir Dis 1992; 145: 947-953.

52. Lauweryns JM, Baert JH. Alveolar clearance and the role of the pulmonary lymphatics. An Rev Respir Dis 1977; 115: 625-683.

53. Meylan P, Richman DD, Kornbluth RS. Reduced intracellular growth of

mycobacteria in human macrophages at physiologic oxygen pressure. An Rev Respir Dis 1992; 145: 947-953.

54. Berger H, Rosenbaum I. Prolonged fever in patients treated for tuberculosis. Am Rev Respir Dis 1968; 97: 140-143.

55. Barnes P, Chan L, Wong S. The course of fever during treatment of pulmonary

tuberculosis. Tubercle 1987; 68: 255-260.

56. Kiblawi S, Jay SJ, Stoneheill RB et al. Fever response of patients on therapy for pulmonary tuberculosis. Am Rev Respir Dis 1981; 123: 20-24.

57. Rooney J, Crocco J, Kramer S. Further observation on tubercolin reaction in tuberculosis. Am J Med 1976; 60: 517-522.

58. Dochin JS, Jereb JA, Nolan CM et al. Comparison of sensitivities to two commercially available tuberculin skin test reagents in person with recent tuberculosis. Clin Infect Dis 1997; 25: 661-663.

59. Khan MA, Kovnat DM, Bachus B et al. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult. Am J Med 1977; 62: 31-38.

60. Miller WT, MacGregor RR. Tuberculosis: frequency of unusual radiographic findings. Am J Roentgenol 1978; 130: 867-875.

61. Farman D, Speir WA Jr. Initial roentgenographic manifestation of bacteriologically proven M. tuberculosis. Typical or atypical? Chest 1986; 89: 75-76.

62. Korzeniewska-kosela M, Krysl J, Muller N et al. Tuberculosis in young adults and the elderly. A prospective comparison study. Chest 1994; 106: 28-32.

63. Jones BE, Ryu R, Young Z et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med 1997;

156: 1270-1273.

64. Im JG, Itoh H, Shim YS. Pulmonary tuberculosis: CT findings-early active disease and sequential change with antituberculous therapy. Radiology 1993; 186: 653- 660.

65. Lee KS, Hwang JW, Chung MP et al. Utility of CT in the evaluation of pulmonary tuberculosis ion patients without AIDS. Chest 1996; 110: 977-984.

66. Cowie RL, Sharpe JW. Extrapulmonary tuberculosis: a high frequency in absence in

HIV infection. Int J Tuberc Lung Dis 1997; 1: 159-162.

67. Grzybowski S, Allen EA. History and importance of scrofula. Lancet 1995;

346:1472-1474.

68. Yew WW, Lee J. Pathogenesis of cervical tuberculous lymphadenitis: pathways to anatomic localization. Tuberc Lung Dis 1995; 76: 275-278.

69. Artenstein AW, Kim JH, Williams WJ et al. Isolated peripheral tuberculous lymphadenitis in adults: current clinical and diagnostic issues. Clin Infect Dis 1995; 20: 876-882.

70. Cantrall RW, Hensen JH, Reid D. Diagnosis and management of tuberculous cervical adenitis. Arch Otolaryngol 1975; 101: 53-57.

71. Ord RF, Matz GJ. Tuberculous cervical lymphadenitis. Arch Otolaryngol 1974;

99:327-329.

72. Stead WW, Eichenholz A, Strauss HK. Operative and pathological findings in twenty-four patients with the syndrome idiopathic pleurisy with effusion presumably tuberculosis. Am Rev Tuberc 1955; 71:473-502.

73. Abrams WB, Small MJ. Current concept of tuberculous pleurisy as derived from pleural biopsy studies. Scand J Respir Dis 1960; 38: 60-65.

74. Antoniskis D, Amin K, Barnes PF. Pleuritis as a manifestation of reactivation tuberculosis. Am J Med 1990; 89: 447-450.

75. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988; 138: 184-234.

76. Christensen WI. Genito-urinary tuberculosis: review of 102 cases. Medicine 1974;

53: 377-390.

77. Centers for Disease Control. Tuberculosis statistics in the United States. Atlanta:

CDC, 1992.

78. Omari B, Robertson JM, Nelson RF et al. Pott’s disease. A resurgent challenge to the

thoracic surgeon. Chest 1989; 95: 145-150.

79. Perez C, Torroba L, Gonzales M et al. Unusual presentation of tuberculous rheumatism (Poncet’s disease) with oral ulcers and tuberculid. Clin Infect Dis 1998; 26: 1003-1004.

80. Wallace R, Cohen AS. Tuberculous arthritis. A report of two cases with review of biopsy and synovial fluid findings. Am J Med 1976; 61: 277-282.

81. Donald PR, Schoeman JF, Beyers N et al. Concentration of interferon γ, tumor necrosis factor α and interleukin-1β in the cerebrospinal fluid of children treated for tuberculous meningitis. Clin Infect Dis 1995; 21: 924-929.

82. Shankar P, Manjunath N, Mohan K et al. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet 1991; 335: 57.

83. Ahuja GK, Mohan KK, Prasad K et al. Diagnostic criteria for tuberculous meningitis and their validation. Tuberc Lung Dis 1994.;75: 149-152.

84. Harrison GN, Chew WH. Tuberculous peritonitis. S Med J 1979; 72: 1561-1588.

85. Paustian FF, Backus HL. So-called primary ulcerohypertrophic ileocecal tuberculosis. Am J Med 1959; 27: 509-518.

86. Richards RJ, Hamwi Y, Rodriguez OS. Intestinal tuberculosis with associated coloduodenal fistula. Clin Infect Dis 1998; 26: 761-762.

87. Hageman JH, D’Esopo ND, Glenn WWL. Tuberculous pericarditis. A long-term analysis of fourty-four proved cases. N Engl J Med 1964; 270: 327-332.

88. Chen CH, Shih JF, Wang LS et al. Tuberculous subcutaneous abscess: an analysis of seven cases. Tuberc Lung Dis 1996; 77: 184-187.

89. Degitz K, Steidl M, Thomas P et al. Aethiology of tuberculids. Lancet 1993;

341:239-240.

90. Schneider JW, Geigeir DH, Rossouw DJ et al. Mycobacterium tuberculosis DNA in erythema induratum of Bazin. Lancet 1993; 342: 747.

91. Spiegel CT, Tuason CU. Tuberculous liver abscess. Tubercle 1984;65: 127-131.

92. Sartin JS, Walker RC. Granulomatous hepatitis: a retrospestive review of 88 cases at the Mayo Clinic. Mayo Clin Proc 1991;66: 914-918.

93. Farer LS, Lowell AM, Meador MP. Extrapulmonary tuberculosis in the United States. Am J Epidemiol 1979; 109: 205-217.

94. Salamina G. La Tubercolosi: screening e misure preventive. Atti del convegno:

Malattie infettive riemergenti, Firenze-Roma 1995; 83-87.

95. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: 221-247

96. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Royal College of Physicians, 2006. London.

97. Guidelines for the investigation of contacts of persons with infectious tuberculosis:

recommendations from the National Tuberculosis Controllers Association and CDC. Centers for Disease Control and Prevention. MMWR 2005.

98. Ferrara G, Losi M, D’Amico R et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006 367(9519):1328-1334.

99. Diel R, Nienhaus A, Lange C, et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006; 7:77.

100. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170(1):65-69.

101. Fitzgerald JM, Gafnni A. A cost-effectiveness analysis of the routine use of

isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev

102. Snider D, Caras G, Kaplan J. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-1583.

103. Nettleman MD, Geerdes H, Roy MC. The cost-effectiveness of preventing

tuberculosis in physicians using teberculin skin-testing or a hypothetical vaccine.

Arch Intern Med 1997; 157: 1121-127.

104. American College of Chest Physicians. American College of Chest Physicians Consensus Conference on tuberculosis. Chest 1985; 87: 1152-1158.

105. Regione Toscana. Giunta Regionale. Protocollo Regionale per il Controllo della Tubercolosi 1998.

106. Sakula A. BCG: who were Calmette and Guerin? Thorax 1983; 38: 806-812.

107. Smith DW. Protective effect of BCG in experimental tuberculosis. In: Fox W, Grosset J, Styblo K. Advances in tuberculosis research. 1985: 1-97 ed.Basel:

Karger.

108. Comstock GW. The international tuberculosis campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 1994; 19: 528-540.

109. American Thoracic Society Documents. American Thoracic Society - Centers for Disease Control and Prevention – Infectious Diseases Society of America:

Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.

110. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 2005; 26: 503-510.

111. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251.

112. Trebucq A. Should ethambutol be recommended for routine treatment of

tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997;

1:12-15

113. Feja K, Saiman L. Tuberculosis in children. Clin Chest Med 2005; 26: 295-312.

114. O’Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005; 26: 327-340

115. Duncan K, Barry CE. Prospects for new antitubercular drugs. Curr Opin Microbiol 2004; 7: 460-465.

116. Pletz MW, de Roux A, Roth A, Neumann KH, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-782

117. Chan CY, Au-Yeang C, Yew WW, Leung CC, Cheng AF. In vitro post-antibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 340-343.

118. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: 1124-1130.

119. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 2005; 9: 248-257.

120. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus:

principles of therapy and revised recommendations. MMWR 1998; 47: 1– 58.

121. Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005; 26: 283

122. Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of

isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001; 119: 1730-

1736.

123. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS et al.

Programmes and principles in treatment of multidrug-resistant tuberculosis.

Lancet 2004; 363: 474 – 481.

124. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.

125. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8:1499-1505.

126. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC et al.

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.

Hepatology 2000; 31:201– 206.

127. Steele M, Burk R, Des Prez R. Toxic hepatitis with isoniazide and rifampin: a meta-analysis. Chest 1991; 99:465-471.

128. Sarma GR, Immanual C, Kailasam S, Narayana AS, Venkatesan P. Rifampin- induced release of hydrazine from isoniazide: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazide and rifampin. Am Rev Respir Dis 1986; 133:1072-1075.

129. Mehta YS, Jijina FF, Badakere SS, Pathare AV, Mohanty D. Rifampicin –induced immune thrombocytopenia. Tuberc Lung Dis 1996; 77:558-562.

130. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

Clin Infect Dis 1997; 24:786-795.

131. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single

daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis

1997; 24:796-809.

132. Leibold J. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135:904-909.

133. Gangadharam PR, Pratt PF, Perumal VK, Iseman MD. The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141:1478-1482.

134. Pilheu J, De Salvo M, Koch O. Liver alterations in antituberculosis regimens

containing pirazinamide. Chest 1979; 80:720-722.